Anixa Biosciences (ANIX) to Release Earnings on Tuesday

Anixa Biosciences (NASDAQ:ANIX) is expected to be announcing its earnings results before the market opens on Tuesday, January 21st. Analysts expect the company to announce earnings of ($0.11) per share for the quarter.

Anixa Biosciences (NASDAQ:ANIX) last announced its earnings results on Friday, January 10th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02.

Anixa Biosciences Trading Down 6.6 %

Shares of ANIX stock opened at $2.41 on Monday. The stock has a market cap of $77.55 million, a PE ratio of -6.18 and a beta of 0.90. The company’s fifty day moving average price is $2.80 and its 200-day moving average price is $3.03. Anixa Biosciences has a 12 month low of $2.07 and a 12 month high of $5.13.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ANIX. D. Boral Capital reiterated a “buy” rating and issued a $10.00 price target on shares of Anixa Biosciences in a research note on Tuesday, January 14th. HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Anixa Biosciences in a research note on Tuesday, November 19th.

Insiders Place Their Bets

In other Anixa Biosciences news, CEO Amit Kumar bought 43,000 shares of the firm’s stock in a transaction on Wednesday, January 15th. The stock was acquired at an average price of $2.23 per share, with a total value of $95,890.00. Following the transaction, the chief executive officer now owns 559,925 shares in the company, valued at $1,248,632.75. This represents a 8.32 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Lewis H. Titterton, Jr. bought 10,000 shares of the firm’s stock in a transaction on Friday, January 17th. The stock was acquired at an average cost of $2.57 per share, with a total value of $25,700.00. Following the transaction, the director now owns 922,334 shares in the company, valued at $2,370,398.38. The trade was a 1.10 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 62,289 shares of company stock valued at $141,561. 22.60% of the stock is owned by insiders.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.